MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/medicina62040763

Медицинская библиотека · Medicina (Kaunas, Lithuania) · 2026

Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study.

Yıldız Fatih, Karabuga Berkan, Karatlı Salih, Yalınkılıç Merve, Deliktas Onur İlknur, Bilgic Koylu Ece, Soylu Kocoğlu Sıla, Eraslan Emrah, Ilhan Gülesen Aysegül, Erdur Erkan, Yildirim Ozgen Ahmet, Gurler Fatih, Yasar Hatime Arzu, Aslan Ferit

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

Background and

Objectives

Neoadjuvant systemic therapy incorporating dual HER2 blockade has significantly improved outcomes in patients with HER2-positive breast cancer. Pathological complete response (pCR) is an important surrogate endpoint associated with improved long-term survival. However, substantial heterogeneity in treatment response persists, and identifying factors associated with pCR remains clinically relevant. In addition to established clinicopathological variables, systemic inflammation-based biomarkers have recently been investigated as potential predictors of treatment response. Materials and

Methods

In this multicenter retrospective study, we evaluated patients with stage II-III HER2-positive breast cancer who received pertuzumab-based neoadjuvant therapy followed by surgery between January 2023 and June 2025 across six oncology centers in Türkiye. Clinicopathological characteristics, treatment-related variables, and baseline systemic inflammation-based biomarkers were analyzed. Logistic regression analyses were performed to identify factors associated with pCR.

Results

A total of 372 patients were included, and the overall pCR rate was 61%. Higher pCR rates were observed in patients with hormone receptor-negative tumors (71.4% vs. 54.3%, p = 0.001) and in premenopausal patients (68.7% vs. 53.4%, p = 0.003). In multivariate analysis, hormone receptor status (OR 2.25, 95% CI 1.41-3.60, p < 0.001), menopausal status (OR 1.90, 95% CI 1.22-2.94, p = 0.005), neoadjuvant treatment regimen (OR 2.15, 95% CI 1.05-4.41, p = 0.037), and perineural invasion (OR 2.61, 95% CI 1.10-6.22, p = 0.030) were independently associated with pCR. In contrast, systemic inflammation-based biomarkers did not demonstrate significant associations with pCR, and ROC analyses showed limited discriminatory ability (AUC values approximately 0.5).

Conclusions

In patients with HER2-positive breast cancer treated with pertuzumab-based neoadjuvant therapy, treatment response appears to be primarily influenced by clinicopathological and treatment-related factors rather than systemic inflammatory status. Peripheral blood inflammatory biomarkers derived from routine laboratory parameters showed limited value in predicting pCR in this setting.

Для цитирования: Yıldız Fatih, Karabuga Berkan, Karatlı Salih, Yalınkılıç Merve, Deliktas Onur İlknur, Bilgic Koylu Ece, Soylu Kocoğlu Sıla, Eraslan Emrah, Ilhan Gülesen Aysegül, Erdur Erkan, Yildirim Ozgen Ahmet, Gurler Fatih, Yasar Hatime Arzu, Aslan Ferit. Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study.. Medicina (Kaunas, Lithuania). 2026. DOI: 10.3390/medicina62040763.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.